116 related articles for article (PubMed ID: 12477997)
1. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Asbury RF; Brunetto VL; Lee RB; Reid G; Rocereto TF;
Am J Clin Oncol; 2002 Dec; 25(6):557-60. PubMed ID: 12477997
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Thigpen T; Brady MF; Homesley HD; Soper JT; Bell J
J Clin Oncol; 2001 Jan; 19(2):364-7. PubMed ID: 11208827
[TBL] [Abstract][Full Text] [Related]
3. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Lentz SS; Brady MF; Major FJ; Reid GC; Soper JT
J Clin Oncol; 1996 Feb; 14(2):357-61. PubMed ID: 8636744
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Whitney CW; Brunetto VL; Zaino RJ; Lentz SS; Sorosky J; Armstrong DK; Lee RB;
Gynecol Oncol; 2004 Jan; 92(1):4-9. PubMed ID: 14751130
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of leuprolide in advanced/recurrent endometrial cancer.
Covens A; Thomas G; Shaw P; Ackerman I; Osborne R; Lukka H; Carey M; Franssen E; Roche K
Gynecol Oncol; 1997 Jan; 64(1):126-9. PubMed ID: 8995560
[TBL] [Abstract][Full Text] [Related]
6. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.
Zidan J; Zohar S; Mijiritzky I; Kral S; Bilenca B
Isr Med Assoc J; 2002 Aug; 4(8):597-9. PubMed ID: 12183859
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
Fleming GF; Filiaci VL; Marzullo B; Zaino RJ; Davidson SA; Pearl M; Makker V; Burke JJ; Zweizig SL; Van Le L; Hanjani P; Downey G; Walker JL; Reyes HD; Leslie KK
Gynecol Oncol; 2014 Mar; 132(3):585-92. PubMed ID: 24456823
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
11. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
12. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
13. Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
Alkasi O; Meinhold-Heerlein I; Zaki R; Fasching P; Maass N; Jonat W; Beckmann MW
Arch Gynecol Obstet; 2009 Jan; 279(1):57-60. PubMed ID: 18379806
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.
Ramirez PT; Frumovitz M; Bodurka DC; Sun CC; Levenback C
Gynecol Oncol; 2004 Oct; 95(1):133-8. PubMed ID: 15385122
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
Miller DS; Blessing JA; Lentz SS; Waggoner SE
Gynecol Oncol; 2002 Dec; 87(3):247-51. PubMed ID: 12468321
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Fiorica JV; Brunetto VL; Hanjani P; Lentz SS; Mannel R; Andersen W;
Gynecol Oncol; 2004 Jan; 92(1):10-4. PubMed ID: 14751131
[TBL] [Abstract][Full Text] [Related]
18. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Lincoln S; Blessing JA; Lee RB; Rocereto TF
Gynecol Oncol; 2003 Mar; 88(3):277-81. PubMed ID: 12648575
[TBL] [Abstract][Full Text] [Related]
19. A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer.
Pautier P; Vergote I; Joly F; Melichar B; Kutarska E; Hall G; Lisyanskaya A; Reed N; Oaknin A; Ostapenko V; Zvirbule Z; Chetaille E; Geniaux A; Shoaib M; Green JA
Int J Gynecol Cancer; 2017 Feb; 27(2):258-266. PubMed ID: 27870712
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
Makker V; Filiaci VL; Chen LM; Darus CJ; Kendrick JE; Sutton G; Moxley K; Aghajanian C
Gynecol Oncol; 2015 Jul; 138(1):24-9. PubMed ID: 25888978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
